DACH1 a key protein for tumor suppression in ER+ breast cancer

Jul 15, 2009

Researchers from the Kimmel Cancer Center at Jefferson have identified a protein relationship that may be an ideal treatment target for ER+ breast cancer. The study was reported in the July 15 issue of Cancer Research.

DACH1, a cell fate determination factor , prevents cancer by repressing the function of receptorsin breast cancer, the researchers found. However, they also found that as the presence of DACH1 decreases in breast cancer, the presence of estrogen receptors increases, and vice versa.

Approximately 70% of breast cancers are ER+. Treatment for ER+ breast cancer usually consists of hormone therapy, which includes lowering the natural estrogen levels in the body or using synthetic drugs like tamoxifen, which compete with natural estrogen. However, this treatment only works for a few years.

"Eventually, will circumvent the estrogen-dependent growth and find a different pathway through which they will proliferate," said Vladimir Popov, a doctoral student in Biochemistry and Molecular Biology at Jefferson College of Graduate Studies of Thomas Jefferson University and the study's first author. "Our lab has shown that there is a correlation between DACH1 and estrogen receptors. DACH1 is a naturally occurring repressor of function in normal breast tissue, which makes it a promising therapeutic target for patients with ER+ breast cancer."

DACH1 is expressed in normal breast tissue. As breast cancer develops and becomes more invasive, the expression of DACH1 decreases. In a previous study of more than 2,000 breast cancer patients, Jefferson researchers found that a lack of DACH1 expression was associated with a poor prognosis. Patients who did express DACH1 lived an average of 40 months longer.

"Many more studies need to be done, but there is strong evidence that DACH1 is a promising marker of survival and therapeutic target in patients with ," said the study's senior researcher Richard Pestell, M.D., Ph.D, who is director of the Kimmel Cancer Center and chair of the Cancer Biology department at Jefferson.

Source: Thomas Jefferson University (news : web)

Explore further: Study finds new potential melanoma drug target

Related Stories

Recommended for you

Study finds new potential melanoma drug target

May 02, 2015

A new treatment for melanoma could be on the horizon, thanks to a finding by a UNC Lineberger Comprehensive Cancer Center-led team. In the study, which was published online today in the journal Clinical Ca ...

Surgery for terminal cancer patients still common

May 02, 2015

The number of surgeries performed on terminally ill cancer patients has not dropped in recent years, despite more attention to the importance of less invasive care for these patients to relieve symptoms and ...

Study provides comprehensive look at brain cancer treatments

May 01, 2015

Led by the Translational Genomics Research Institute (TGen) and UC San Francisco (UCSF), a comprehensive genetic review of treatment strategies for glioblastoma brain tumors was published today in the Oxford University Press ...

How artificial tanning can lead to melanoma

May 01, 2015

Young women may be up on the latest fashions and trends as they prepare for prom season. But what many don't know is that the tan that looks oh-so-good with their dress may be the first step toward skin cancer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.